Gastrointestinal stromal tumors (GISTs): From science to targeted therapy

R. Sarmiento, P. Bonginelli, F. Cacciamani, F. Salerno, Giampietro Gasparini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs represent a distinct category of tumors characterized by oncogenic mutations of the KIT receptor tyrosine kinase in a majority of patients. KIT is useful not only for the diagnosis but also for targeted therapy of this disease. Imatinib, a tyrosine kinase inhibitor, is widely used in advanced and metastatic GISTs. This agent revolutionized the treatment strategy of advanced disease and is being tested in the neoadjuvant and adjuvant settings with encouraging results. New therapeutic agents like sunitinib have now been approved, enriching the treatment scenario for imatinib-resistant GISTs. The present review reports on the peculiar characteristics of this disease through its biology and molecular patterns, focusing on the predictive value of KIT mutations and their correlation with clinical outcome as well as on the activity of and resistance to approved targeted drugs.

Original languageEnglish
Pages (from-to)96-110
Number of pages15
JournalInternational Journal of Biological Markers
Volume23
Issue number2
Publication statusPublished - Apr 2008

Fingerprint

Gastrointestinal Stromal Tumors
Tumors
Mutation
Receptor Protein-Tyrosine Kinases
Therapeutics
Protein-Tyrosine Kinases
Gastrointestinal Tract
Molecular Biology
Neoplasms
Pharmaceutical Preparations
Imatinib Mesylate

Keywords

  • GISTs
  • Targeted therapy
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Sarmiento, R., Bonginelli, P., Cacciamani, F., Salerno, F., & Gasparini, G. (2008). Gastrointestinal stromal tumors (GISTs): From science to targeted therapy. International Journal of Biological Markers, 23(2), 96-110.

Gastrointestinal stromal tumors (GISTs) : From science to targeted therapy. / Sarmiento, R.; Bonginelli, P.; Cacciamani, F.; Salerno, F.; Gasparini, Giampietro.

In: International Journal of Biological Markers, Vol. 23, No. 2, 04.2008, p. 96-110.

Research output: Contribution to journalArticle

Sarmiento, R, Bonginelli, P, Cacciamani, F, Salerno, F & Gasparini, G 2008, 'Gastrointestinal stromal tumors (GISTs): From science to targeted therapy', International Journal of Biological Markers, vol. 23, no. 2, pp. 96-110.
Sarmiento R, Bonginelli P, Cacciamani F, Salerno F, Gasparini G. Gastrointestinal stromal tumors (GISTs): From science to targeted therapy. International Journal of Biological Markers. 2008 Apr;23(2):96-110.
Sarmiento, R. ; Bonginelli, P. ; Cacciamani, F. ; Salerno, F. ; Gasparini, Giampietro. / Gastrointestinal stromal tumors (GISTs) : From science to targeted therapy. In: International Journal of Biological Markers. 2008 ; Vol. 23, No. 2. pp. 96-110.
@article{40284e7e2f6540b3b6a0fbfccd030b80,
title = "Gastrointestinal stromal tumors (GISTs): From science to targeted therapy",
abstract = "Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs represent a distinct category of tumors characterized by oncogenic mutations of the KIT receptor tyrosine kinase in a majority of patients. KIT is useful not only for the diagnosis but also for targeted therapy of this disease. Imatinib, a tyrosine kinase inhibitor, is widely used in advanced and metastatic GISTs. This agent revolutionized the treatment strategy of advanced disease and is being tested in the neoadjuvant and adjuvant settings with encouraging results. New therapeutic agents like sunitinib have now been approved, enriching the treatment scenario for imatinib-resistant GISTs. The present review reports on the peculiar characteristics of this disease through its biology and molecular patterns, focusing on the predictive value of KIT mutations and their correlation with clinical outcome as well as on the activity of and resistance to approved targeted drugs.",
keywords = "GISTs, Targeted therapy, Tyrosine kinase inhibitors",
author = "R. Sarmiento and P. Bonginelli and F. Cacciamani and F. Salerno and Giampietro Gasparini",
year = "2008",
month = "4",
language = "English",
volume = "23",
pages = "96--110",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "2",

}

TY - JOUR

T1 - Gastrointestinal stromal tumors (GISTs)

T2 - From science to targeted therapy

AU - Sarmiento, R.

AU - Bonginelli, P.

AU - Cacciamani, F.

AU - Salerno, F.

AU - Gasparini, Giampietro

PY - 2008/4

Y1 - 2008/4

N2 - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs represent a distinct category of tumors characterized by oncogenic mutations of the KIT receptor tyrosine kinase in a majority of patients. KIT is useful not only for the diagnosis but also for targeted therapy of this disease. Imatinib, a tyrosine kinase inhibitor, is widely used in advanced and metastatic GISTs. This agent revolutionized the treatment strategy of advanced disease and is being tested in the neoadjuvant and adjuvant settings with encouraging results. New therapeutic agents like sunitinib have now been approved, enriching the treatment scenario for imatinib-resistant GISTs. The present review reports on the peculiar characteristics of this disease through its biology and molecular patterns, focusing on the predictive value of KIT mutations and their correlation with clinical outcome as well as on the activity of and resistance to approved targeted drugs.

AB - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs represent a distinct category of tumors characterized by oncogenic mutations of the KIT receptor tyrosine kinase in a majority of patients. KIT is useful not only for the diagnosis but also for targeted therapy of this disease. Imatinib, a tyrosine kinase inhibitor, is widely used in advanced and metastatic GISTs. This agent revolutionized the treatment strategy of advanced disease and is being tested in the neoadjuvant and adjuvant settings with encouraging results. New therapeutic agents like sunitinib have now been approved, enriching the treatment scenario for imatinib-resistant GISTs. The present review reports on the peculiar characteristics of this disease through its biology and molecular patterns, focusing on the predictive value of KIT mutations and their correlation with clinical outcome as well as on the activity of and resistance to approved targeted drugs.

KW - GISTs

KW - Targeted therapy

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=52249107509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249107509&partnerID=8YFLogxK

M3 - Article

C2 - 18629782

AN - SCOPUS:52249107509

VL - 23

SP - 96

EP - 110

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 2

ER -